Results 241 to 250 of about 926,997 (405)

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Adaptation and validation of the Chinese version of the digital addiction scale for children (DASC). [PDF]

BMC Public Health
Xu J, Ma Y, Tan M, Lou J, Lu J, Zhou X.
europepmc   +1 more source

Addiction to Methadone among Patients at Lexington and Fort Worth [PDF]

, 1968
Joseph D. Sapira, John C. Ball, Emily Cottrell   +2 more
openalex   +1 more source

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

Molecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
wiley   +1 more source

Recreational Use of Nitrous Oxide – a Growing Concern in Europe

Emerging Trends in Drugs, Addictions, and Health
Introduction: Nitrous oxide, commonly known as laughing gas, is used medically as an analgesic and anaesthetic. It has been used recreationally for its brief euphoric effects for over 200 years, however, in the last decade, there has been a large ...
J. De Morais, L. Van Aerts, M. Evans-Brown, A. Gallegos, R. Christie, R. Jorge, T. Néfau, G. Planchuelo, R. Sedefov, C. Victorri-Vigneau, R. Povilanskiene, K. Grasaasen, D.F.t. Palmqvis, D. Mongan, K. Killeen, A.O. Duarte, A.S. Santos   +16 more
doaj  

Integrating hepatology with addiction care for inpatients with alcohol use disorder reduces future liver-related events. [PDF]

Hepatol Commun
George P, Marshall C, Zhang W, Goodman R, Butler M, Patel SJ, Mitchell M, Schaefer E, Luther J.   +8 more
europepmc   +1 more source

New Drugs of Addiction [PDF]

, 1965
P. A. L. Chapple
openalex   +1 more source

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

Molecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow   +10 more
wiley   +1 more source

Drug Peddling, Addiction, and Criminalism

, 1932
Mary D. Bailey
openalex   +2 more sources

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source